Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Deep anterior lamellar keratoplasty after Descemet's stripping automated endothelial keratoplasty

Poster Details

First Author: S. Gutfreund ITALY

Co Author(s):    P. Leon   S. Graffi   R. Spena   V. Scorcia   M. Busin        

Abstract Details


To report the indications and long term outcomes of Deep Anterior Lamellar Keratoplasty (DALK) after Descemet Stripping Automated Endothelial Keratoplasty (DASEK) in cases of visual restricting stromal opacities


Ophthalmology Department, Vila Igea Private Hospital, Forli, Italy


The medical records of all patients who had undergone DALK after DSAEK at Villa Serena-Villa Igea Private Hospital were reviewed. Indications for the subsequent DALK surgery included both residual post-DSAEK stromal opacity and stromal opacity occurring in a formerly clear stroma. Best corrected visual acuity (BCVA),manifest refraction and endothelial cell density were assessed preoperatively and postoperatively.


Thirteen eyes from 13 patients who had undergone DALK after DSAEK were identified. Mean follow-up time after DALK was 23 months (Range 6 to 46). Indications for DASEK were: failed PK (N=8), failed DSAEK (N=3) and Pseudophakic bullous keratopathy (N=2).Indications for DALK post-DSAEK included residual stromal opacity (n=9), post-DSAEK herpetic keratitis (n=2) and post-DSAEK interface infection (n=2).No intraoperative complication occurred in any case. BCVA improved in 12 out of 13 eyes. Mean post-operative BCVA in all eyes without ocular comorbidities was 20/30.After complete suture removal, mean refractive cylinder was 3.2±1.4D, with all but one eye ending up with ≤ 4.00D.


Performing a DALK on DSAEK is a safe procedure with favorable visual results that allows 'closed system' surgery while avoiding the replacement of an healthy endothelial graft..

Financial Disclosure:

One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing